Being exposed to rhodamine B (RhB), a toxic fluorescent dye, causes neurodegeneration and symptoms that resemble amyotrophic lateral sclerosis (ALS) in zebrafish, a study reports. The exposed zebrafish exhibited behaviors, and cellular and molecular changes similar to those in neurological disorders like ALS. Their muscles and motor abilities also…
News
Far-field potentials (FFPs), weak electrical signals triggered by nerve stimulation that can be recorded noninvasively on the skin, may serve as reliable clinical biomarkers to support early diagnosis and disease monitoring in people with amyotrophic lateral sclerosis (ALS), a study suggests. The strength of these signals, or FFP amplitude,…
Neuvivo and the U.S. Food and Drug Administration (FDA) have agreed on a regulatory pathway toward the potential approval of NP001 for amyotrophic lateral sclerosis (ALS), with Phase 3 clinical testing planned for 2026. The details were agreed upon in a Type C meeting and the pivotal…
In amyotrophic lateral sclerosis (ALS), the loss of any one of four RNA-binding proteins turns off a gene called UNC13A that needs to stay active for nerve cells to communicate with each other — with three of them leading to an excess of another protein, REST — pointing to…
Full randomization is nearly complete in the Phase 2/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS), its developer, Medicinova, reported. Fewer than 10 participants remain to be assigned to a treatment group. The ongoing COMBAT-ALS trial (NCT04057898) aims to evaluate…
A new coalition aims to use artificial intelligence (AI) tools to accelerate drug discovery for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Answer ALS is teaming with partners including GATC Health — a drug discovery company focusing on machine learning and neural networks — Louisiana State…
AB Science has been cleared to start its confirmatory Phase 3 trial of masitinib for people with amyotrophic lateral sclerosis (ALS) in the U.S. and certain European countries. The company announced plans for the Phase 3 AB23005 trial earlier this year, noting then that the trial…
NKGen Biotech said it’s been cleared to launch an expanded access program (EAP) that will allow patients in the U.S. with neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), to access its experimental therapy troculeucel outside clinical trials. EAPs, or compassionate use programs, allow people with serious or life-threatening conditions…
The ALS Association has announced the winners of its first-ever Hoffman ALS Clinic Development and Capacity Awards, two new grant programs aimed at improving access to multidisciplinary care for people with amyotrophic lateral sclerosis (ALS) across the U.S. The awards are supported by a $58 million donation from the…
The ongoing program that is providing amyotrophic lateral sclerosis (ALS) patients with access to Medicinova’s investigational therapy MN‑166 (ibudilast) outside of a clinical trial is adding new sites. The expanded access program (EAP) will enroll about 200 patients at several locations in the U.S. who are not eligible…
Recent Posts
- Feeding wildlife reminded me what’s important in life after ALS
- Inflammatory bacterial sugar in gut may drive ALS risk: Study
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS